INILUNSAD ng Philippine Drug Enforcement Agency (PDEA) at ng Dangerous Drugs Board (DDB) ang digital system na magmo-monitor sa regulated dangerous drugs at pigilan ang dibersyon ng chemicals na gamit sa paggawa ng illegal substances, noong Nobyembre 16, 2021.
“Dangerous Drugs and Controlled Precursors and Essential Chemicals Monitoring System (DDCPEC-MS), the web-enabled information program is designed to receive, gather, collect and collate all data and information on the importation, exportation, production, manufacture, distribution, dispensing, sale, stocks, seizures and estimated need for any dangerous drugs and/or CPECs from any agency of the government, private person or enterprise dealing in or engaged in such activities,” ayon sa PDEA
Sinabi pa ng PDEA, ang monitoring system ay isang reportorial requirement mula sa United Nations Commission on Narcotic Drugs (UN-CND), World Health Organization (WHO) at iba pang international organizations.
Ang development at implementasyon ng DDCPEC-MS ay pinatibay sa pamamagitan ng pirmahan ng Memorandum of Agreement (MOA) sa pagitan nina DDB Chairman Secretary Catalino S. Cuy, at PDEA Director General Wilkins M. Villanueva.
“The DDCPEC-MS acts a single-window reporting mechanism where all regulated transactions and activities of dangerous drugs, and CPECs, with legitimate medical and industrial use, including chemical mixtures, preparations and finished products containing the same, are received from manufacturers, importers, exporters and distributors,” ani Villanueva.
“The DDCPEC-MS gives us a huge lift in determining the compliance of pharmaceutical and chemical entities handling dangerous drugs and CPECs in the country,” dagdag pa niya.
Ang PDEA, sa pamamagitan ng Compliance Service, ay nagsasanay sa regulatory functions para isama sa pagproseso at issuance ng mga lisensya at permits sa pharmaceutical at chemical establishments na nauugnay sa importasyon, distribusyon, paggawa, preskripsyon, pamimigay at pagbebenta at iba pang batas na may kinalaman sa ano mang dangerous drugs at CPECs, at iba pang kapareho o analogous substances. (JOEL O. AMONGO)
168 
